Immunotherapies – What do Primary Care Providers Need to Know?

This presentation will introduce primary care providers to the mechanism of action of immunotherapies, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies and review several common immune-related adverse events. This presentation will also review the treatment of immune-related adverse events and offer best practices for primary care providers that co-manage patients with cancer.

*Due to rapidly changing clinical knowledge, once purchased, you have 90 days access to complete this education.

Credits: 1.0 Contact Hours; 1.00 are Pharmacology
This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid from 3/12/2025 to 3/11/2026 . PAs should only claim credit commensurate with the extent of their participation. 
Expiration Date: March 11, 2026

$27.50

LEARNING OBJECTIVES

After taking part in this educational activity, participants should be better able to:

-As a result of this activity the learner will be able to understand the mechanism of action of immunotherapies, specifically immune checkpoint inhibitors (ICI) and chimeric antigen receptor (CAR) T-cell therapies.

-As a result of this activity the learner will be able to identify certain immune-related adverse events (IrAEs), including cytokine release syndrome (CRS), and Immune effector cell-associated neurotoxicity syndrome (ICANs).

-As a result of this activity the learner will be able to identify best practices for co-managing patients on immunotherapies.

CE/CME INFORMATION

Obtain Your Credits

To earn credits for this activity, navigate to the Content(s) tab and complete all course components in the following order: 1) watch the course presentation video; 2) complete the course evaluation; 3) pass the post-test with a score of 2/3 (66.7%) or higher. You may retake the post-test until a passing score is achieved, at which point you will be able to view/print a copy of your certificate of completion. This online certificate will also be saved within your profile 'My Courses/Certificates' -> 'Transcript/Certificates Earned'  for future access.

Designation Statement

NPACE designates this educational activity for a maximum of 1.0 contact hours, of which 1.00 is pharmacology credit. Participants should claim only credit commensurate with the extent of their participation in the activity.

This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid from 3/12/2025 to 3/11/2026 . 

Accreditation Statement

Nurse Practitioner Associates for Continuing Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

In addition to ANCC, NPACE is approved as a provider of continuing education in nursing by: the California Board of Registered Nursing, Provider Number CEP8720

This activity has been reviewed by the American Academy of Physician Associates Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid from 3/12/2025 to 3/11/2026 . PAs should only claim credit commensurate with the extent of their participation.

DISCLOSURES

Faculty

Contributing faculty, Rose DiMarco, PharmD, BCPS, BCOP has disclosed:

CE Synergy Independent Consultant/Advisory Board Oncology Varies
Lilly Lecture Bureau Faculty, Consultant Oncology Verzenio
Pharmacy and Healthcare Communications Independent Consultant/Advisory Board Oncology Varies
Acclinate Independent Consultant/Advisory Board Oncology Multiple Myeloma
Gilead Independent Consultant/Advisory Board Oncology Trodelvy
Horizon CME Planning Committee Member Oncology

Planners

All planne.rs and contributors involved in this educational activity have disclosed no relevant financial relationships. 

Disclaimer

The material presented in this continuing education program is being made available for educational purposes only and is not intended to represent the best or only methods, medications and/or guidelines appropriate for the medical situation discussed. Rather the material is intended to present an approach, view, statement, or opinion of the presenter(s), which may be helpful, or of interest to other practitioners and should not be used by clinicians without the evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. NPACE disclaims any liability, loss, injury, or damage incurred as a consequence, directly or indirectly, of the use and application of any information given in a presentation.

Disclosure of Unlabeled Use

This educational activity may mention the uses of products that are not approved by the FDA for the indication(s) being discussed. The presenter(s) are instructed to notify participants when they are discussing unapproved uses or investigational agents. The opinions related to unapproved uses of products are solely those of the presenter(s) and are not endorsed or recommended by NPACE. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Commercial Support

There is no commercial support for this activity.